scispace - formally typeset
D

Do Young Kim

Researcher at Yonsei University

Publications -  737
Citations -  18320

Do Young Kim is an academic researcher from Yonsei University. The author has contributed to research in topics: Hepatocellular carcinoma & Medicine. The author has an hindex of 58, co-authored 674 publications receiving 15091 citations. Previous affiliations of Do Young Kim include University of Ulsan & Fred Hutchinson Cancer Research Center.

Papers
More filters
Journal ArticleDOI

Radiomics on Gadoxetic Acid-Enhanced Magnetic Resonance Imaging for Prediction of Postoperative Early and Late Recurrence of Single Hepatocellular Carcinoma.

TL;DR: The prognostic value of the preoperative radiomic model with 3-mm border extension showed comparable performance with that of the postoperative clinicopathologic model for predicting DFS of early recurrence of H CC using gadoxetic acid–enhanced MRI, suggesting the importance of including peritumoral changes in the radiomic analysis of HCC.
Journal ArticleDOI

Assessments of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in Korean patients with psoriasis vulgaris and psoriatic arthritis

TL;DR: Elevated NLR and PLR were strong predictors for the presence of PsA among psoriasis patients and were significantly associated with the increased PASI scores in multivariate analysis.
Journal ArticleDOI

Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma.

TL;DR: F-fluorodeoxyglucose positron emission tomography is a useful imaging modality for identifying extrahepatic metastases which may lead to accurate staging and proper management of patients with possible extrahePatic metastasis.
Journal ArticleDOI

How can we enhance the performance of liver stiffness measurement using FibroScan in diagnosing liver cirrhosis in patients with chronic hepatitis B

TL;DR: Different cutoff LSM values according to alanine aminotransferase level and combination with age-spleen-platelet ratio index can enhance the performance of LSM in CHB, regardless of ALT level.
Journal ArticleDOI

Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: Single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma

TL;DR: This work evaluated prognostic values of Barcelona Clinic Liver Cancer (BCLC) stage compared with other staging systems, and identified discrepancies between treatment options chosen in Korean clinical practice and BCLC guidelines.